Page 63 - GTM-4-1

Global Translational Medicine Incretins and cardiorenal disease

latest-in-cardiology/articles/2024/04/15/11/19/glp1ras-in- doi: 10.1155/2022/6820377
clinical-practice [Last accessed on 2024 Nov 02].
44. Farr OM, Mantzoros CS. Treating prediabetes in the
41. Hathaway JT, Shah MP, Hathaway DB, et al. Risk of obese: Are GLP-1 analogues the answer? Lancet. 2017;389:
nonarteritic anterior ischemic optic neuropathy in patients 1371-1372.
prescribed semaglutide. JAMA Ophthalmol. 2024:e242296. doi: 10.1016/S0140-6736(17)30315-X
doi: 10.1001/jamaophthalmol.2024.2296 45. Hoffmann C, Schwarz PE, Mantzoros CS, et al. Circulating
42. Małyszczak A, Przeździecka-Dołyk J, Szydełko-Paśko U, levels of gastrointestinal hormones in prediabetes reversing
Misiuk-Hojło M. Novel antidiabetic drugs and the risk to normoglycemia or progressing to diabetes in a year-A
of diabetic retinopathy: A systematic review and meta- cross-sectional and prospective analysis. Diabetes Res Clin
analysis of randomized controlled trials. J Clin Med. 2024; Pract. 2023;199:110636.
13(6):1797. doi: 10.1016/j.diabres.2023.110636
doi: 10.3390/jcm13061797 46. Le KDR, Le K, Foo F. The impact of glucagon-like peptide
43. Xu D, Nair A, Sigston C, et al. Potential roles of glucagon- 1 receptor agonists on obstructive sleep apnoea: A scoping
like peptide 1 receptor agonists (GLP-1 RAs) in nondiabetic review. Pharmacy (Basel). 2024;12(1):11.
populations. Cardiovasc Ther. 2022:6820377. doi: 10.3390/pharmacy12010011

Volume 4 Issue 1 (2025) 55 doi: 10.36922/gtm.4405